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Abstract
Introduction In cancer, an extracellular and membrane
bound localization of cathepsins contribute to the invasion
of tumor cells at the basement membrane.
Methods This is the Wrst study that explored levels of
cathepsins B (CatB), L (CatL) and their inhibitor cystatin C
(CysC) in the cystic Xuid (CF) of ovarian tumors (n = 110).
Results CF contained considerable amounts of CatB,
CatL and CysC. Remarkable diVerences in CatB and CatL
and CysC CF levels were found between diVerent histopa-
thological tumor subtypes. Levels of CatB and CysC were
signiWcantly higher in CF of malignant serous tumors com-
pared to those found in benign serous tumors (p = 0.010
and p = 0.001 respectively), whereas levels of CatL were
signiWcantly higher in CF of malignant mucinous tumors
compared to those found in benign mucinous tumors
(p = 0.035). CatB and CysC showed a strong correlation in
the group of patients with malignant serous tumors
(p <0 . 0 0 1 ;   R = 0.921) suggesting that the increase in CatB
might be balanced by a corresponding increase in CysC.
Conclusion Further studies are warranted to investigate
cathepsins as possible prognostic biomarkers for the
aggressiveness of ovarian cancer.
Keywords Ovarian cancer · Cathepsin · Cystatin · Cyst 
Xuid · Ovarian tumor
Introduction
Epithelial ovarian cancer (EOC) is the most lethal gyneco-
logical malignancy worldwide. Because of the absence of
early symptoms, approximately 70% of the patients are
diagnosed with FIGO stage III or IV, when tumor cells
already have metastasized to the upper abdomen (Colombo
et al. 2006). Compared to other types of cancer, insight into
the carcinogenesis and progression of ovarian cancer is lim-
ited by the lack of a well-deWned precursor lesion and by
the lack of data from early-stage cancers (Landen et al.
2008).
In neoplastic transformation, the epithelial surface Wrst
becomes multicell layered. Tumor cells then degrade the
basement membrane and invade the stroma or become
detached from the primary tumors and metastasize (Capo-
Chichi et al. 2002; Scully 1995; Feeley and Wells 2001;
Aznavoorian et al. 1993). It is now widely believed that the
degradation of the basement membrane is catalyzed by pro-
teolytic enzymes (Liotta et al. 1980; Turk et al. 2000; DuVy
1996). Among these enzymes are the lysosomal cysteine
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proteinases or cathepsins, which have an important physio-
logical function in regulation of intracellular protein metab-
olism. The human family of cathepsins has 11 members
(cathepsin B, C, F, H, K, L, O, S, V, W and X), which share
a conserved active site that is formed by cysteine, histidine
and asparagine residues. In cancer tissue, an increased
expression of cathepsins has been described and an extra-
cellular and membrane-bound localization of particularly
cathepsin B (CatB) and cathepsin L (CatL) has been dem-
onstrated, which might contribute to the invasion of tumor
cells at the basement membrane (Turk et al. 2000; Kos
et al. 2000; Premzl et al. 2006).
Numerous reports have now been published investigating
cancer tissue expression of cathepsins (DuVy  1996;
Schwartz 1995; Sloane et al. 1990). Although quantitation of
cathepsins in extracellular Xuid has several advantages com-
pared to measurement in tissue, reports investigating extra-
cellular cathepsin levels are rather limited (Kos et al. 2000).
Higher levels of CatB and CatL were reported in sera of
patients with several types of cancer (Gabrijelcic et al. 1992;
Kos et al. 1997, 1998; Leto et al. 1997a; Strojan et al. 2001;
Zore et al. 2001; Bhuvarahamurthy and Govindasamy
1995), including ovarian cancer (Nishida et al. 1995;
Warwas et al. 1997), compared to levels in healthy subjects
or patients with benign lesions. The possibility of measuring
cathepsins in blood increases its clinical value as a tumor
marker, but reported levels in the serum are signiWcantly
lower than levels in tumor cells of cancer patients (Kos et al.
2000). Lah et al. (1992) have shown that CatB was present
in ascites of patients with ovarian carcinoma. Moreover,
they showed that extracellular CatB was inhibited most
strongly by cystatin C (CysC), which is an extracellular cys-
teine proteinase inhibitor (Lah et al. 1992). Recent studies
on tissue of breast and ovarian cancer and melanoma
showed that an imbalance of CatB/CysC (zonder levels) was
correlated with a more aggressive tumor behavior (Kos et al.
1997; Nishikawa et al. 2004; Yano et al. 2001).
Most ovarian tumors exhibit, sometimes multiple, cysts
that can be large. The cyst Xuid (CF) is in close contact
with the tumor tissue. To our knowledge, no studies have
been performed to investigate the levels of cathepsins or
their endogenous inhibitors in this ovarian CF. In the pres-
ent study, we explored CatB, CatL as well as CysC levels in
CF of patients with benign, borderline and malignant ovar-
ian tumors.
Materials and methods
Patients and cyst Xuid collection
From our biobank containing ovarian cyst Xuid (CF) sam-
ples of patients with ovarian tumors who underwent
primary surgery at the Radboud University Nijmegen
Medical Center in the period between 1988 and 1998, small
portions of all 110 CF samples were retrieved. Samples in
this biobank were collected by aseptic Wne needle aspira-
tion at the department of pathology immediately after surgi-
cal removal of the tumor. After cooled transport to the
laboratory, the CF samples were centrifuged at 3,000£g for
10 min and the supernatant was stored at ¡35°C in small
portions until use. Histopathological diagnosis was per-
formed by an experienced gynecologic pathologist and
revealed 74 benign, 26 malignant and 10 borderline epithe-
lial ovarian tumors. Informed consent was obtained from all
participants.
ELISA procedures
For the quantitative analysis of CatB, CatL and CysC in
ovarian CF, commercially available speciWc ELISAs
(sandwich ELISAs, Krka d.d., Novo mesto, Slovenia)
were used, as developed by Kos et al. (1997) at Joqef Ste-
fan Institute, Ljubljana, Slovenia. The components were
puriWed and characterized, and the tests were optimized
and performed as described (Kos et al. 1995). To deWne
the optimal dilution, CF samples were serially diluted to
the levels encompassing the range of the assays. The line-
arity of the response was evaluated by comparing the mea-
sured values with the calibration curves. The recovery was
tested by the addition of diVerent amounts of the antigen to
the samples with known antigen concentration that varied
from 88 to 108%, comparing expected versus observed
concentrations. The intra-assay coeYcient of variance var-
ied from 7.6 to 12.7%. CF samples were diluted 1:4 for
CatB and CatL and 1:100 for CysC prior to being applied
to the wells of microtiter plate. A microplate reader (SLT
Rainbow, Salzburg, Austria) was used to measure absor-
bance. Determination of the levels of cathepsins and CysC
was carried out without prior knowledge of the histologi-
cal or clinical outcome.
Parameters for aggressiveness of the tumor
From the pathology and medical reports of the patients with
EOC, the following parameters were retrieved: histopatho-
logic subtype and histopathologic grade, age at diagnosis
and FIGO stage of disease. Histopathologic subtype and
tumor grade were classiWed according to the World Health
Organization (WHO) criteria (Servov et al. (1973)). Stag-
ing was performed using the International Federation of
Gynaecologists and Obstetricians (FIGO) criteria (Pecorelli
et al. 1999). In case of uncertainty about the primary loca-
tion of the tumor, extensive immunohistochemical staining
was performed. Only patients with conWrmed primary EOC
were included.J Cancer Res Clin Oncol (2010) 136:771–778 773
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Statistical analyses
Values are shown as median with range (ng/ml). Normality
of distributions was analyzed by Kolmogorov–Smirnov
testing. Data regarding CatB, CatL and CysC could be nor-
malized by Ln transformation. DiVerences between two
groups were tested by Student’s t test, and for more than
two groups by ANOVA and subsequent post hoc Tukey’s
HSD tests. Correlations were assessed by Pearson correla-
tion tests of the Ln-transformed values. A priori signiW-
cance was set at a two-sided P < 0.05. All statistical
analyses were performed using SPSS version 16.0.01
(SPSS Inc. Chicago IL, USA).
Results
The mean age at diagnosis was 40 years (SD § 14) for
patients with benign ovarian tumors (n = 74), 42 years
(SD § 14) for patients with borderline ovarian tumors
(n = 10) and 57 years (SD § 11) for patients with EOC
(n = 26). The mean age of patients with ovarian cancer was
signiWcantly higher than that of patients with benign
(p < 0.001, Student’s t test) and borderline tumors
(p = 0.009, Student’s t test). No diVerences in mean age
were found between patients with benign and borderline
tumors (p = 0.898, Student’s t test).
Histopathological subtype
Table 1 shows the median (range) concentrations of CatB,
CatL and CysC in ovarian CF of patients with malignant,
borderline and benign ovarian tumors, grouped by histolog-
ical subtype. Within the benign group, CF levels of CatL
were signiWcantly diVerent between serous cystadenomas
and mucinous cystadenomas (p = 0.003) and between
endometriosis cysts and mucinous cystadenomas
(p < 0.001). Although generally not signiWcantly diVerent
from the other benign histological subtypes, the median
concentrations of CatB and CatL in cystic endometriosis
were remarkably high and comparable to those found in CF
of malignant tumors. CysC concentrations were in the same
range for all benign subclasses. Within the group of border-
line and malignant tumors, CF levels of CatB, CatL and
CysC did not diVer signiWcantly between histopathological
subtypes.
Table 2 and Fig. 1 show median (range) CF levels of
CatB, CatL and CysC in benign (cystadenoma), borderline
and malignant (cystadenocarcinoma) ovarian tumors
according to the histopathological subtype. In serous
Table 1 Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst Xuid (n = 110) grouped by histopathological
subtypes
* A single concentration is listed. Statistical signiWcance according to ANOVA (p = 0.001) with Tukey’s HSD post hoc test of values normalized
after Ln transformation
a p = 0.003 for mucinous cystadenomas compared to serous cystadenomas
b p < 0.001 for mucinous cystadenomas compared to cystic endometriosis
Histology N (%) Cathepsin B Cathepsin L Cystatin C
Benign
Serous cystadenoma 29 (39) 12 (1–269) 31 (9–121)a 572 (131–1,781)
Mucinous cystadenoma 21 (28) 16 (1–227) 11 (1–95)a, b 578 (39–9,984)
Dermoid cyst 5 (7) 11 (1–108) 10 (2–97) 618 (117–876)
Cystic endometriosis 16 (22) 71 (1–177) 69 (8–233)b 338 (92–1,931)
Corpus luteum cyst 3 (4) 18 (6–98) 15 (15–133) 644 (520–1,805)
Borderline
Serous borderline tumor 2 (20) 14 (8–21) 28 (18–38) 1,449 (1,125–1,772)
Mucinous borderline tumor 6 (60) 31 (2–118) 75 (8–166) 697 (474–3,897)
Mixed-type borderline tumor* 1 (10) 227 92 340
Unknown 1 (10)
Malignant
Serous cystadenocarcinoma 10 (38) 65 (3–269) 61 (8–163) 1,443 (448–5,972)
Mucinous cystadenocarcinoma 8 (31) 33 (5–269) 31 (13–187) 959 (399–9,984)
Endometrioid cystadenocarcinoma 6 (23) 85 (1–269) 71 (14–181) 1,200 (64–2,907)
Mixed-type cystadenocarcinoma* 1 (4) 95 67 1,232
UndiVerentiated cystadenocarcinoma* 1 (4) 110 75 109774 J Cancer Res Clin Oncol (2010) 136:771–778
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tumors (n = 41), CF levels of CatB were signiWcantly
higher for patients with malignant tumors compared to
patients with benign tumors (p = 0.010), whereas CatL lev-
els did not diVer signiWcantly within this histological sub-
group. In contrast, in mucinous tumors (n = 35), CF levels
of CatL were signiWcantly higher for patients with malig-
nant tumors compared to patients with benign tumors
(p = 0.035), whereas CatB levels did not diVer within this
histological subgroup. CF levels of CysC only diVered
between patients with malignant and benign tumors in the
subgroup of serous tumors (p = 0.001).
Parameters of aggressiveness of the tumor
Table 3 shows clinicopathological parameters of tumor
aggressiveness and median (range) concentrations of CatB,
CatL and CysC of the 26 patients with EOC. Since no
diVerences in CF levels of CatB, Cat L and CysC were
found between serous, mucinous and endometrioid cystade-
nocarcinomas (Table 1), data of patients with EOC were
merged. When patients were grouped according to FIGO
stage of disease, tumor grading and presence of ascites, no
signiWcant diVerences in CF levels of CatB, CatL and/or
CysC were found.
Correlation between cathepsins and cystatin C
Figure 2 shows the scatter plots of the correlation between
Cathepsins and Cystatin C for patients with serous (Fig. 2a
and 2b; n = 41) and mucinous (Fig. 2c; n =3 5 )  t u m o r s .  F o r
serous tumors, CF levels of CysC and CatB were signiW-
cantly correlated (p < 0.001, R = 0.652, Fig. 2a). The corre-
lation between CF levels of CysC and CatB was highest for
the malignant group (p < 0.001, R = 0.921). For mucinous
tumors, CF levels of CysC and CatB did not show any rela-
tionship (p = 0.923,  Wgure not shown). Correlations
between CF levels of CysC and CatL were signiWcant for
both serous and mucinous tumors (p = 0.001,  R = 0.491,
Fig. 2b and p = 0.003; R = 0.481, Fig. 2c, respectively). For
mucinous tumors, the correlation between CF levels of
CysC and CatL was highest for the benign group
(p < 0.001, R =0 . 6 6 5 ) .
Discussion
In this study, we examined ovarian CF levels of CatB, CatL
and their extracellular inhibitor CysC. In benign tumors,
remarkable diVerences in CF levels of cathepsins B and L
were found between diVerent histopathological subtypes.
For serous tumors, the levels of CatB and CysC were sig-
niWcantly higher in the CF of patients with EOC compared
to CF levels of patients with benign ovarian tumors. For
mucinous tumors, the levels of CatL were signiWcantly
higher in the CF of patients with EOC compared to CF lev-
els of patients with benign ovarian tumors. Furthermore,
correlations between cyst Xuid levels of CatB and CysC
and between CatL and CysC were found. Finally, we inves-
tigated the relationship between the levels of CatB, CatL
and CysC and parameters of tumor aggressiveness of EOC,
but could not Wnd signiWcant diVerences between the sub-
groups of patients.
We are the Wrst to describe that CF of ovarian tumors
contains considerable amounts of CatB, CatL and CysC. In
ascitic  Xuid of patients with ovarian cancer, Lah et al.
(1992) found CatB and a large pool of free CysC. We
showed that CF levels of these enzymes were higher in
ovarian cancer patients compared to patients with benign
Table 2 Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst Xuid (n = 67) of benign, borderline and malignant
tumors grouped by serous and mucinous subtype
* Statistical signiWcance according to ANOVA
Student’s t testa, b, c of values normalized after Ln transformation
a p = 0.010 for serous cystadenoma compared to serous cystadenocarcinoma
b p = 0.001 for serous cystadenoma compared to serous cystadenocarcinoma
c p = 0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinoma
Subtype N (%) Cathepsin B p-value* Cathepsin L p-value* Cystatin C p-value*
Serous 41 0.031 0.131 0.001
Serous cystadenoma 29 (71) 12 (1–269)a 31 (9–121) 572 (131–1,780)b
Serous borderline tumor 2 (5) 14 (8–21) 28 (18–38) 1,449 (1,125–1,772)
Serous cystadenocarcinoma 10 (24) 65 (3–269)a 61 (8–163) 1,443 (448–5,972)b
Mucinous 35 0.315 0.017 0.136
Mucinous cystadenoma 21 (60) 16 (1–227) 11 (1–95)c 578 (39–9,984)
Mucinous borderline tumor 6 (17) 32 (2–118) 75 (8–166) 697 (474–3,897)
Mucinous cystadenocarcinoma 8 (23) 33 (5–269) 31 (13–187)c 959 (399–9,984)J Cancer Res Clin Oncol (2010) 136:771–778 775
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ovarian tumors. Serum studies in patients with other types
of cancer have demonstrated similar results, as levels of
CatB, CatL and CysC were found to be higher in serum of
patients with cancer compared to serum levels of patients
with benign tumors or healthy controls (Gabrijelcic et al.
1992; Kos et al. 1997, 1998; Leto et al. 1997a, b; Strojan
et al. 2001; Zore et al. 2001; Yano et al. 2001; Makarewicz
et al. 1995; Miyake et al. 2004; Strojan et al. 2004; Mulao-
merovic et al. 2007). In serum of patients with ovarian can-
cer, Warwas et al. (1997) found higher levels of CatB
compared to the levels in patients with benign ovarian
tumors. On the other hand, Nishikawa et al. (2004) could
not observe a signiWcant diVerence in serum CatB level
between patients with benign ovarian tumors and ovarian
cancer, although they did Wnd a signiWcantly higher level of
CysC in the serum of patients with ovarian cancer. Only
one study has been published investigating CatL in the
serum of patients with ovarian tumors (Nishida et al. 1995).
The authors found that the serum levels of CatL were ele-
vated in 8/10 patients with ovarian cancer compared to 2/10
patients with benign ovarian tumors.
The mean age of patients with ovarian cancer is known
to be signiWcantly higher than that of patients with benign
ovarian tumors (Merino and JaVe  1993). This was also
found in our study group. This might confound our results,
as there is deWnite evidence that renal function decreases
with age (Lindeman and Goldman 1986), which results in a
reduced glomerular Wltration rate in older people. CysC is
known to be almost completely reabsorbed and catabolized
in the proximal renal tubular cells (Stabuc et al. 2000). This
might explain the higher serum levels of CysC that were
reported earlier in patients with ovarian cancer compared to
that in patients with benign ovarian tumors. However, we
found no correlation in CF between age and CysC level
within the subgroups of patients. In addition, it is unclear
whether CysC levels in ovarian CF, in contrast to serum,
are inXuenced by renal function. Finally, the group of
patients with borderline tumors was of similar age as the
patients with benign tumors, yet exhibited CatB, CatL and
CysC levels similar to those of patients with ovarian can-
cer. The level of CysC might be changed also due to patho-
logical renal failures, changing the glomerular Wltration rate
in cancer patients (Stabuc et al. 2000). However, patients
included in this study, did not exhibit any impaired kidney
Fig. 1 Box plots of the (a) cathepsin B and (b) cathepsin L, and (c)
cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst
Xuid for patients with malignant, borderline and benign ovarian
tumors, clustered by histological subtype (serous and mucinous
tumors). Statistical signiWcance above the subWgures are according to
ANOVA (P < 0.05) with Tukey’s HSD post hoc tests of values nor-
malized after Ln transformation
776 J Cancer Res Clin Oncol (2010) 136:771–778
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function. Therefore, we believe that the results of CysC in
this study have not been biased by age-related or pathological
changes of kidney function.
Remarkably, CatB and CysC CF levels were signiW-
cantly higher in malignant serous tumors compared to
benign serous tumors, whereas CatL CF levels were signiW-
cantly higher in malignant mucinous tumors compared to
benign mucinous tumors. This Wnding contributes to the
theory that malignant serous and mucinous ovarian tumors
are diVerent diseases, with subtype-speciWc biomarker pro-
Wles (Heinzelmann-Schwarz et al. 2006; Kobel et al. 2008;
Cloven et al. 2004). In addition, a signiWcant correlation
between CatB and CysC was found for patients with serous
tumors. Moreover, the correlation of CatB and CysC was
extremely strong in the group of patients with malignant
serous tumors (R = 0.921), which might indicate that an
increase of CF CatB in malignant tumors was balanced by a
corresponding increase in CF CysC level. This Wnding
could be interesting, as it was proposed in previous studies
that a relative imbalance between CatB and CysC in
patients with cancer might contribute to the invasion and
metastasis of tumor cells (Kos et al. 2000; Nishikawa et al.
2004; Lah et al. 2000).
Although not signiWcant, median CF levels of CatB and
CatL were up to seven times higher in cystic endometriosis
compared to the other histopathological subtypes, and lev-
els were comparable to CF levels of ovarian cancer patients
with unfavorable tumor characteristics. Noteworthy is that
CysC did not diVer between cystic endometriosis and other
benign subtypes, which might suggest a diVerent balance
between CatB and CysC in endometriosis cysts compared
to the other histological subtypes. This might be explained
by the continuous breakdown of components of blood and
stromal tissue in endometriosis without a malignant inva-
sion or metastasis. However, it is now well established that
endometriosis does have neoplastic potential and it has
been associated with the development of endometrioid and
clear-cell ovarian carcinoma (Feeley and Wells 2001;
Wells 2004).
Since ovarian cancer tissue is highly heterogeneous,
multiple biopsies are necessary for a careful examination
(Hogdall et al. 2007; Chauhan et al. 2007). This means that
quantitation of cathepsins and cystatins in biological Xuids
of ovarian cancer patients has several clinical advantages
over measurements in ovarian cancer tissue. We found that
the levels of cathepsins and CysC in ovarian CF were much
higher than that in serum of cancer patients, as reported in
literature. More speciWcally, up to six times more CatB was
found in CF than in the serum of patients with colorectal
carcinoma (Kos et al. 1998) and melanoma (Kos et al.
1997), up to ten times more CatL was found in ovarian CF
Fig. 2 Scatter plots of Ln-transformed values of cyst Xuid cystatin C
with cathepsin B (a) and cathepsin L (b) for patients with serous
tumors (n = 41) and cystatin C with cathepsin L (c) for patients
with mucinous tumors (n = 35). Statistical signiWcance (p <0 . 0 5 )  a n d
correlation coeYcient (R) according to Pearson’s correlation test.
Asterisks malignant; open triangles borderline, open circles benignJ Cancer Res Clin Oncol (2010) 136:771–778 777
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than in serum of patients with ovarian cancer (Nishida et al.
1995), and up to eight times more CysC was found in ovar-
ian CF than in the serum of patients with ovarian cancer
(Nishikawa et al. 2004). This might indicate that CatB,
CatL as well as CysC are released from tumor cells into the
CF to a greater extent than the release of these compounds
into the serum of cancer patients. In this way, CF values
may give a better reXection of local changes of the ovarian
tumor than levels of cathepsins and its inhibitors in serum,
which also might be aVected by the systemic response on
malignant disease and circadian variations (Cimerman et al.
1999, 2000). From a clinical perspective, preoperative aspi-
ration of ovarian cyst Xuid might cause iatrogenic metasta-
sis of tumor cells, and ovarian cyst Xuid can only be used as
a source of biomarkers for predicting prognosis and
response to therapy. We, therefore, investigated the rela-
tionship between clinicopathological parameters that corre-
spond with tumor aggressiveness and the levels of CatB,
CatL and CysC in patients with ovarian cancer. However,
when patients were grouped according to FIGO stage of
disease, tumor grading and presence of ascites, no signiW-
cant diVerences in CF levels of CatB, CatL and/or CysC
were found. This could be caused by the relatively small
size of cyst Xuid samples from malignant tumors in the
present study.
Conclusions
CF levels of CatB, and its endogenous inhibitor CysC, were
signiWcantly higher in serous EOC compared to benign
serous ovarian tumors, whereas CF levels of Cat L were
signiWcantly higher in mucinous EOC compared to benign
mucinous ovarian tumors. The correlation between CatB
and CysC was extremely strong for patients with serous
EOC, which might indicate that an increase in CatB of
these patients is balanced by a corresponding increase in
CysC level. We feel that further studies with a larger series
of samples from malignant tumors are needed to explore
the possible prognostic value of cathepsins and CysC in
ovarian CF.
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